Search Results 211-220 of 17437 for Mmol

1. Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer - Mayo Clinic

   mg/dL [7.7 mmol/L], or glycosylated hemoglobin [HbA1c] level of >6.4%). 3. Known intolerance to alpelisib or any of its excipients. 4. Patient is currently ...

2. A Study to Evaluate the Safety and Tolerability of LCZ696 Followed by a 52-week Study of LCZ696 Compared With Enalapril in Pediatric Patients with Heart Failure - Mayo Clinic

   Serum potassium > 5.3 mmol/L at Visit 1 or at Visit 301. Patients with significant renal (eGFR calculated using the modified Schwartz formula < 30% mean GFR ...

3. A Study of Pembrolizumab (MK-3475) Versus Placebo in Combination with Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer - Mayo Clinic

   Hemoglobin* ≥ 9 g/dL or ≥ 5.6 mmol/L. Renal. Creatinine ≤ 1.5 × ULN; OR; Measured or calculated** creatinine clearance (GFR can also be used instead of ...

4. A Study to Establish a New Onset Hyperglycemia and Diabetes Cohort - Mayo Clinic

   2h Post Glucose (PG) ≥ 200mg (11.1 mmol/L) during OGTT (oral glucose tolerance test); OR. Any (1) PDM present followed by an anti-diabetes medication ...

5. A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495) - Mayo Clinic

   6 mmol/L*. Renal. Creatinine OR Measured or calculated** creatinine clearance (GFR can also be used in place of creatinine or CrCl);; ≤1.5 × ULN OR ≥0 mL ...

6. A Study to Assess the Efficacy and Safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) - Mayo Clinic

   ... mmol/L) - Subject has impaired renal function as defined by an eGFR <90 mL/min - Subject has a total absence of fucosylation on red blood cells and the ...

7. A study to test whether survodutide helps people with a liver disease called NASH/MASH who have cirrhosis - Mayo Clinic

   HbA1c > 10% (> 86 mmol/mol) as measured by the central laboratory at screening. History of T1DM or any other type than type 2 (e.g. endocrinopathy, genetic ...

8. A Study to Investigate the Impact of Pregnancy on Glomerular Filtrate Rate (GFR) Outcomes in Females with Primary Hyperoxaluria (PH) - Mayo Clinic

   Urinary oxalate excretion of greater than 0.8 mmol/1.73 m2/day (>70 mg/1.73 m2/day) in the absence of a gastrointestinal disease known to cause hyperoxaluria ( ...

9. Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) - Mayo Clinic

   Hemoglobin ≥9 g/dL or ≥5.6 mmol/L; Hematocrit ≥30%. Renal function: Creatinine ≤1.5x ULN OR measured or calculated creatinine clearance (Glomerular ...

10. Trial Using Keytruda as Initial Therapy in the Treatment of Advanced Mycosis Fungoides - Mayo Clinic

    Hemoglobin ≥ 9.0 g/dL or ≥ 5.6 mmol/L without transfusion or EPO dependency (within 7 days of assessment);; Serum total bilirubin ≤ 1.5 X ULN OR Direct ...